Inhibikase Therapeutics, Inc. Selling, General and Administrative Expense
Inhibikase Therapeutics, Inc. (IKT) reported Selling, General and Administrative Expense of $7.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $7.66M, a 29.36% increase year-over-year.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $7.38M, a 40.52% increase year-over-year.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $6.77M, a 18.12% increase year-over-year.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $5.61M, a 242.67% increase year-over-year.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for fiscal 2025 was $23.56M, a 107.01% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for fiscal 2024 was $11.38M, a 69.02% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for fiscal 2023 was $6.73M, a 8.28% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. selling, general and administrative expense for fiscal 2022 was $6.22M, a 4.47% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.66M 10-Q · filed 2026-08-11 | $15.03M 10-Q · filed 2026-08-11 | $21.81M derived: sum of 3 quarters · filed 2026-08-11 | $27.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.38M 10-Q · filed 2026-05-12 | $14.15M derived: sum of 2 quarters · filed 2026-05-12 | $19.76M derived: sum of 3 quarters · filed 2026-05-12 | $25.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $12.39M derived: sum of 2 quarters · filed 2026-03-26 | $18.31M derived: sum of 3 quarters · filed 2026-08-11 | $23.56M 10-K · filed 2026-03-26 |
| 2025-09-30 | $5.61M 10-Q · filed 2025-11-14 | $11.53M derived: sum of 2 quarters · filed 2026-08-11 | $16.78M 10-Q · filed 2025-11-14 | $22.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $5.92M 10-Q · filed 2026-08-11 | $11.17M 10-Q · filed 2026-08-11 | $16.90M derived: sum of 3 quarters · filed 2026-08-11 | $18.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.25M 10-Q · filed 2026-05-12 | $10.98M derived: sum of 2 quarters · filed 2026-05-12 | $12.62M derived: sum of 3 quarters · filed 2026-05-12 | $14.60M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.37M derived: sum of 2 quarters · filed 2026-03-26 | $9.35M derived: sum of 3 quarters · filed 2026-03-26 | $11.38M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.64M 10-Q · filed 2025-11-14 | $3.61M derived: sum of 2 quarters · filed 2025-11-14 | $5.64M 10-Q · filed 2025-11-14 | $7.04M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.97M 10-Q · filed 2025-08-14 | $4.01M 10-Q · filed 2025-08-14 | $5.41M derived: sum of 3 quarters · filed 2025-08-14 | $7.03M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.03M 10-Q · filed 2025-05-14 | $3.43M derived: sum of 2 quarters · filed 2025-05-14 | $5.05M derived: sum of 3 quarters · filed 2025-05-14 | $6.84M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.02M derived: sum of 2 quarters · filed 2025-03-27 | $4.81M derived: sum of 3 quarters · filed 2025-03-27 | $6.73M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.62M 10-Q · filed 2023-11-14 | $3.41M derived: sum of 2 quarters · filed 2023-11-14 | $5.33M 10-Q · filed 2023-11-14 | $6.68M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $1.78M 10-Q · filed 2023-08-14 | $3.71M 10-Q · filed 2023-08-14 | $5.05M derived: sum of 3 quarters · filed 2024-05-15 | $6.59M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $1.93M 10-Q · filed 2024-05-15 | $3.27M derived: sum of 2 quarters · filed 2024-05-15 | $4.81M derived: sum of 3 quarters · filed 2024-05-15 | $6.47M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $2.88M derived: sum of 2 quarters · filed 2024-03-27 | $4.55M derived: sum of 3 quarters · filed 2024-03-27 | $6.22M 10-K · filed 2024-03-27 |
| 2022-09-30 | $1.54M 10-Q · filed 2023-11-14 | $3.20M derived: sum of 2 quarters · filed 2023-11-14 | $4.87M 10-Q · filed 2023-11-14 | $6.53M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.66M 10-Q · filed 2023-08-14 | $3.33M 10-Q · filed 2023-08-14 | $4.99M derived: sum of 3 quarters · filed 2023-08-14 | $6.63M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.67M 10-Q · filed 2023-05-15 | $3.32M derived: sum of 2 quarters · filed 2023-05-15 | $4.97M derived: sum of 3 quarters · filed 2023-05-15 | $6.58M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.30M derived: sum of 2 quarters · filed 2023-03-31 | $4.91M derived: sum of 3 quarters · filed 2023-03-31 | $6.51M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.64M 10-Q · filed 2022-11-14 | $3.25M derived: sum of 2 quarters · filed 2022-11-14 | $4.85M 10-Q · filed 2022-11-14 | $6.00M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.61M 10-Q · filed 2022-08-12 | $3.21M 10-Q · filed 2022-08-12 | $4.35M derived: sum of 3 quarters · filed 2022-08-12 | $4.93M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.60M 10-Q · filed 2022-05-16 | $2.74M derived: sum of 2 quarters · filed 2022-05-16 | $3.33M derived: sum of 3 quarters · filed 2022-05-16 | $3.70M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.73M derived: sum of 2 quarters · filed 2022-03-31 | $2.10M derived: sum of 3 quarters · filed 2022-03-31 | $2.62M 10-K · filed 2022-03-31 |
| 2020-09-30 | $580.82K 10-Q · filed 2021-11-15 | $951.15K derived: sum of 2 quarters · filed 2021-11-15 | $1.48M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $370.33K 10-Q · filed 2021-08-16 | $898.02K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $527.69K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |